Streetbeat News

Earnings

BMY

Bristol Myers Squibb & Co (NYSE:BMY) reported better-than-expected Q3 earnings with revenues of $10.966 billion and adjusted EPS of $2.00. However, the company's shares fell 3.8% to $50.94 following the announcement. Several analysts, including those from HSBC, Barclays, Morgan Stanley, William Blair, and BMO Capital, have revised their price targets and ratings for the company.

Portfolio Pulse from Lisa Levin

October 27, 2023 | 5:47 pm

CPT

Camden Property Trust's shares are trading lower following the company's Q3 sales results, which were below expectations.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 5:45 pm

MGRC

McGrath RentCorp (MGRC) shares are trading higher following the company's announcement of better-than-expected Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 5:44 pm

INSM

Insmed shares are trading lower following the company's mixed Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 5:43 pm

PFSI

PennyMac Financial Services reported mixed Q3 financial results, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 5:43 pm

EGO

Eldorado Gold Corporation reported mixed Q3 financial results, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 5:42 pm

OLN

Olin Corporation reported lower than expected sales results for Q3, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 5:41 pm

MA

Mastercard Inc (NYSE:MA) reported better-than-expected Q3 earnings with net revenues of $6.53 billion, up 14% Y/Y and 11% Y/Y on a neutral currency basis, beating the consensus of $6.52 billion. Adjusted EPS rose 26% Y/Y to $3.39, exceeding the consensus of $3.21. Despite the positive results, several analysts including Keybanc, Raymond James, Morgan Stanley, BMO Capital, and RBC Capital lowered their price targets on Mastercard.

Portfolio Pulse from Lisa Levin

October 27, 2023 | 5:39 pm

HAS

Hasbro Inc reported a 10% YoY decline in Q3 FY23 sales to $1.503 billion, missing the analyst consensus estimate of $1.644 billion. The company also revised its FY23 revenue forecast to a decline of 13%-15%, from the previous estimate of 3%-6%. Following the announcement, Hasbro's shares fell 4.4% and several analysts cut their price targets on the company.

Portfolio Pulse from Lisa Levin

October 27, 2023 | 5:34 pm

ACXP

APLM

ATXI

BTCY

COCH

GNLX

ICU

PTCT

PXMD

RNAZ

SNY

ZYXI

During Friday's intraday session, several healthcare stocks experienced significant movements. Apollomics, SeaStar Medical Holding, Envoy Medical, Avenue Therapeutics, Zynex, and Acurx Pharmaceuticals saw gains, while Biotricity, TransCode Therapeutics, PTC Therapeutics, Sanofi, PaxMedica, and Genelux experienced losses. The movements were influenced by trading volumes and recent Q3 earnings reports.

Portfolio Pulse from Benzinga Insights

October 27, 2023 | 5:31 pm